Supernus Pharmaceuticals (SUPN) EPS (Weighted Average and Diluted) (2016 - 2025)
Historic EPS (Weighted Average and Diluted) for Supernus Pharmaceuticals (SUPN) over the last 15 years, with Q3 2025 value amounting to -$0.8.
- Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) fell 21594.2% to -$0.8 in Q3 2025 from the same period last year, while for Sep 2025 it was -$0.34, marking a year-over-year decrease of 13177.57%. This contributed to the annual value of $1.32 for FY2024, which is 649997.6% up from last year.
- Latest data reveals that Supernus Pharmaceuticals reported EPS (Weighted Average and Diluted) of -$0.8 as of Q3 2025, which was down 21594.2% from $0.4 recorded in Q2 2025.
- In the past 5 years, Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) ranged from a high of $0.69 in Q3 2024 and a low of -$0.8 during Q3 2025
- In the last 5 years, Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) had a median value of $0.14 in 2022 and averaged $0.14.
- Its EPS (Weighted Average and Diluted) has fluctuated over the past 5 years, first skyrocketed by 190000.0% in 2024, then crashed by 952064.45% in 2025.
- Quarter analysis of 5 years shows Supernus Pharmaceuticals' EPS (Weighted Average and Diluted) stood at $0.04 in 2021, then surged by 950.0% to $0.42 in 2022, then tumbled by 95.24% to $0.02 in 2023, then skyrocketed by 1273.96% to $0.27 in 2024, then plummeted by 391.13% to -$0.8 in 2025.
- Its EPS (Weighted Average and Diluted) stands at -$0.8 for Q3 2025, versus $0.4 for Q2 2025 and -$0.21 for Q1 2025.